Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: Analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis

Thorax

Volumn 71, Issue 5, 2016, Pages 429-435

  Nathan, Steven D ^a   Albera, Carlo ^b   Bradford, Williamson Z ^c   Costabel, Ulrich ^d   Du Bois, Roland M ^e   Fagan, Elizabeth A ^c   Fishman, Robert S ^c   Glaspole, Ian ^f   Glassberg, Marilyn K ^g   Glasscock, Kenneth F ^c   King, Talmadge E ^h   Lancaster, Lisa ⁱ   Lederer, David J ^j   Lin, Zhengning ^c   Pereira, Carlos A ^k   Swigris, Jeffrey J ^l   Valeyre, Dominique ^m   Noble, Paul W ⁿ   Wells, Athol U ^o  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c InterMune Inc   (United States)

^d RUHRLANDKLINIK   (Germany)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f MONASH UNIVERSITY   (Australia)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^j NewYork Presbyterian Hospital   (United States)

^k FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^l DEPARTMENT OF MEDICINE   (United States)

^m AVICENNE HOSPITAL   (France)

ⁿ CEDARS SINAI MEDICAL CENTER   (United States)

^o ROYAL BROMPTON HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; IDIOPATHIC PULMONARY FIBROSIS; KAPLAN MEIER METHOD; METHODOLOGY; MORTALITY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VITAL CAPACITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; KAPLAN-MEIER ESTIMATE; PYRIDONES; RESEARCH DESIGN; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84961700565     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-207011     Document Type: Article

References (17)

1. Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-9.
3. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A Phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-92.
4. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-82.
5. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-9.
6. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-42.
7. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543-8.
8. Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171: 639-44.
9. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 830-6.
10. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 459-66.
11. Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012; 67: 407-11.
12. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142: 963-7.
13. Cohen J. Statistical power analysis for behavioral sciences. 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
14. Schmidt SL, Tayob N, Han MK, et al. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest 2014; 145: 579-85.
15. Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir Med 2014; 2: 933-42.
16. Richeldi L. Idiopathic pulmonary fibrosis: current challenges and future perspectives. Eur Respir Rev 2013; 22: 103-5.
17. du Bois RM, Nathan SD, Richeldi L, et al. Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med 2012; 186: 712-15.